The Real Time Polymerase Chain Reaction Technique Is Vital In Early Detection Of Covid-19
Early detection plays a key role in treating Covid-19 patients. The real time RT-PCR (polymerase chain reaction) technique is a highly sensitive and specific testing method that can deliver a reliable diagnosis in as fast as three hours, unlike the other laboratory tests that take an average of 6 to 8 hours. Real time RT-PCR is significantly faster and has a lower potential for contamination or errors as the entire process is within a closed tube. Therefore, currently it is considered to be the most accurate method available for detection of the coronavirus. This has created huge demand for PCR testing kits.
The polymerase chain reaction (PCR) and real-time polymerase chain reaction (PCR) testing market consists of sales of PCR and real –time PCR testing services and its related products. Polymerase chain reaction (PCR) and real time polymerase chain reaction testing establishments manufacture, develop or deploy the related devices, reagents and services, to detect and measure the DNA (or RNA) in a sample. It finds its applications in cloning, genotyping, mutation testing, paternity testing, sequencing and microarrays.
The need for early detection of chronic diseases is expected to drive the market. With the onset of chronic diseases, there has been a priority to detect the cause of the disease to decrease its onset on people, for the drug discovery and to start the appropriate treatment at the appropriate time which enables faster cure and also saves maximum lives and decreases its after-effects. The Real time RT-PCR test is the standard test for the recent COVID-19 (corona virus) pandemic. It is used for its high sensitivity which enables it to detect early infection. Therefore, the need for early detection is thought to be propelling the PCR and real time PCR testing market.
The global polymerase chain reaction (PCR) and real-time polymerase chain reaction (PCR) testing market is expected to grow from $7.5 billion in 2019 to about $22.4 billion in 2020 as there is a surge in the number of tests being conducted for the diagnosis of Covid-19. The market is expected to stabilize and reach $10.1 billion at a compound annual growth rate (CAGR) of 7.9% through 2023.
Companies in the PCR and real time PCR testing market are coming with new test kits and systems for the diagnosis of diseases. Recently, Roche has come up with the adenovirus test for transplant patients. It is designed to be used along with other infectious diseases tests which can be used in their 6800 and 8800 cobas systems. More and more companies are coming with the real time RT-PCR test for corona virus, thus new product launches are anticipated to be the trend in the PCR and real time PCR testing market.